Sugi Predict

Sugi Predict / Compounds / Cypenamine

Cypenamine

Cypenamine

SCHEMBL295252

N[C@@H]1CCC[C@@H]1c1ccccc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 10/20 0.60
▸ MAOB P27338 9/20 0.60
▸ MAOA P21397 7/20 0.60
▸ CYP2C19 P33261 4/20 0.60
▸ CYP2B6 P20813 3/20 0.60
▸ CYP1A2 P05177 2/20 0.60
▸ CYP2D6 P10635 2/20 0.60
▸ CYP2C9 P11712 2/20 0.60
▸ LMNA P02545 2/20 0.60
▸ TAAR1 Q96RJ0 2/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ HTR1A P08908 1/20 0.60
▸ ADRA2A P08913 1/20 0.60
▸ CYP2A6 P11509 1/20 0.60
▸ SLC6A2 P23975 1/20 0.60
▸ HTR2C P28335 1/20 0.60
▸ ADRA1A P35348 1/20 0.60
▸ DRD3 P35462 1/20 0.60
▸ SLC6A3 Q01959 1/20 0.60
▸ KCNH2 Q12809 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cypenamine SCHEMBL13813781 1.00 KDM1A (0.60) KDM1AMAOBMAOACYP2C19CYP2B6
Cypenamine SCHEMBL293405 1.00 KDM1A (0.60) KDM1AMAOBMAOACYP2C19CYP2B6
Cypenamine SCHEMBL4418958 1.00 KDM1A (0.60) KDM1AMAOBMAOACYP2C19CYP2B6
Cypenamine SCHEMBL12261999 1.00 KDM1A (0.60) KDM1AMAOBMAOACYP2C19CYP2B6
Cypenamine SCHEMBL293404 1.00 KDM1A (0.60) KDM1AMAOBMAOACYP2C19CYP2B6
Cypenamine SCHEMBL7307497 0.98 MAOB (0.61) KDM1AMAOBMAOACYP2C19CYP2B6
Cypenamine SCHEMBL119769 0.98 MAOB (0.61) KDM1AMAOBMAOACYP2C19CYP2B6
Cypenamine SCHEMBL7316865 0.98 MAOB (0.61) KDM1AMAOBMAOACYP2C19CYP2B6
SCHEMBL10494836 0.95 MAOB (0.60) KDM1AMAOBMAOACYP2C19CYP2B6
SCHEMBL12261925 0.95 MAOB (0.60) KDM1AMAOBMAOACYP2C19CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233858-B1 ERK INHIBITORS MERCK SHARP & DOHME (US) 2019-10-30 — — EP disclosed
US-9884048-B2 ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-06 — — US disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 — — US disclosed
US-20150065490-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-03-05 — — US disclosed
US-8344004-B2 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2013-01-01 — — US disclosed
EP-2240474-B1 CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-03-14 — — EP disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 — — US disclosed
EP-1937659-B1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2010-11-10 — — EP disclosed
EP-2240474-A1 CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2010-10-20 — — EP disclosed
US-7683181-B2 Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof SANOFI-AVENTIS (FR) 2010-03-23 — — US disclosed
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 — — US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 — — EP disclosed
WO-2004016601-A1 BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY NOVARTIS AG (CH) 2004-02-26 — — WO disclosed
US-6639107-B1 Potentiating glutamate receptor function ELI LILLY AND COMPANY 2003-10-28 — — US disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 — — WO disclosed
EP-0563132-B1 TETRAPEPTIDE DERIVATIVES AND ANALOGUES BLACK JAMES FOUNDATION (GB) 1996-02-07 — — EP disclosed
US-5486597-A GASTRIN ANTAGONIST AS ANTISECRETORY AGENTS OF GASTRIC JUICE FOR STOMACH CANCER JAMES BLACK FOUNDATION LIMITED (GB) 1996-01-23 — — US disclosed
EP-0563132-A1 TETRAPEPTIDE DERIVATIVES AND ANALOGUES. BLACK JAMES FOUNDATION (GB) 1993-10-06 — — EP disclosed
WO-1992011284-A1 TETRAPEPTIDE DERIVATIVES AND ANALOGUES THE JAMES BLACK FOUNDATION LIMITED (GB) 1992-07-09 — — WO disclosed
US-4350685-A ASTHMA TREATMENT SMITHKLINE CORPORATION (US) 1982-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266167-A1 ERK INHIBITORS MAPK1, MAPK3, MAPK6 KDM1A 2624/4885MAOB 2764/4885MAOA 3119/4885
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 KDM1A 1543/4885MAOB 1440/4885MAOA 1391/4885
US-20150065490-A1 ORGANIC COMPOUNDS ADRB2, ADRA2C, ADRB1 KDM1A 3819/4885MAOB 227/4885MAOA 272/4885
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals PPARD, PPARG, PPARA KDM1A 3892/4885MAOB 2787/4885MAOA 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.